HIF-1α agonists, such as small molecule hypoxia-inducing factor-prolyl hydroxylase inhibitor GSK1278863, used in clinical trials to treat anemia caused by chronic kidney disease without serious adverse effects50. This evidence concerns the gene HIF1A and chronic kidney disease.